Skip to main content

Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment

Publication ,  Journal Article
Friedman, HS
Published in: Oncology Report
September 1, 2006

Duke Scholars

Published In

Oncology Report

EISSN

1548-5323

ISSN

1548-5323

Publication Date

September 1, 2006

Issue

FALL

Start / End Page

11

Related Subject Headings

  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Friedman, H. S. (2006). Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment. Oncology Report, (FALL), 11.
Friedman, H. S. “Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment.” Oncology Report, no. FALL (September 1, 2006): 11.
Friedman HS. Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment. Oncology Report. 2006 Sep 1;(FALL):11.
Friedman, H. S. “Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment.” Oncology Report, no. FALL, Sept. 2006, p. 11.
Friedman HS. Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment. Oncology Report. 2006 Sep 1;(FALL):11.

Published In

Oncology Report

EISSN

1548-5323

ISSN

1548-5323

Publication Date

September 1, 2006

Issue

FALL

Start / End Page

11

Related Subject Headings

  • Oncology & Carcinogenesis